IFF Launches ESG 2030 ‘Do More Good Plan’
14.12.2021 00:15:00 EET | Business Wire | Press release
IFF (NYSE:IFF) today announced its environmental, social and governance (ESG) roadmap for the combined Company. The 2030 ‘Do More Good Plan’ (the Plan) includes ambitious targets that are aligned with IFF’s purpose of applying science and creativity for a better world.
“With our Do More Good Plan, we are taking another bold step in our aspirations to do more for people, planet and product,” said Andreas Fibig, IFF Chairman & CEO. “Ten years ago, when we formalized our sustainability program, we knew the journey would lead us to being even better partners with our customers, communities and stakeholders. To date, our efforts have achieved ratings above industry standards and have had real impact throughout our value chain. Today, we are going further. With this Plan, we are embedding even more ambitious targets, in our operations and partnerships, to address the urgent issues that affect our world.”
The Plan comprises four key areas:
1. Environmental
To support environmental stewardship across its operations, IFF will accelerate its commitment to climate action by setting new science-based ambitions to reduce greenhouse gas emissions (GHGs) by 50% below 2021 levels by 2030; to achieve net zero GHGs by 2040; and to be net positive by 2050.1 By 2030, IFF will also verify zero waste to landfill, including plastics minimization, for all major manufacturing facilities, and champion water stewardship solutions within its operations. Additionally, the Company commits to accelerating its responsible sourcing practices by promoting regenerative ecosystems and achieving zero deforestation for strategic raw material supply chains by 2030, beginning with palm, soy and wood.
2. Social
Aligned with its social responsibility targets, IFF is advancing its commitment to people and communities. Milestones include strengthening diversity, equity & inclusion within its workforce by having 40% people of color in management roles in the United States by 2030, with equitable representation in other markets globally; and aiming for greater gender balance with women holding 50% of all management roles, companywide. IFF is also committed to continuously improving its safety program by striving for an injury-free workplace, and achieving world-class safety performance. Within its responsible sourcing program, the Company will continue to promote human rights and animal welfare, while supporting farmers’ livelihoods and ensuring prosperous and equitable value chains.
3. Governance
To enhance accountability in line with evolving stakeholder expectations, the Company will launch ESG metrics tied to executive compensation and will expand oversight for ESG at the Board of Directors level. IFF remains on track to increase its transparency in disclosures and key performance indicators.
4. Sustainable Solutions
IFF will assist its customers in achieving their own ESG goals by delivering an expanded suite of sustainable solutions for the market. With this focus on sustainable growth, IFF intends for all new innovations to have a sustainability value proposition that supports people and planet with health & wellbeing products, solutions for sustainable food systems and circular economy strategies. As one of its climate action aspirations, the Company aims to enable customers and consumers to save at least 50 times more CO2e than generated at IFF’s own manufacturing sites by providing innovation solutions such as sustainable proteins as well as enzymes solutions which enable food waste reduction and energy savings.
“Our purpose is inextricably tied to securing a better, more sustainable world,” said Dr. Greg Yep, EVP, Chief Research & Development, Global Integrated Solutions and Sustainability Officer. “This Plan is designed to build on our long-standing commitments to people and planet while showcasing our strengths in science, technology and innovation. As a next step, we are operationalizing these ambitions and their action plans across our divisions and functions so that, together, we will achieve our goals and hold ourselves accountable in meaningful and measurable ways.”
Today’s announcement builds on IFF’s track record of ESG accomplishments, including the following:
2021
- CDP “A” list designation for climate change, water security and forests.
- Dow Jones Sustainability Indices placement, 2nd consecutive year.
- Best Place to Work for LGBTQ Equality award, 3rd consecutive year.
- Best Place to Work for Disability Inclusion award, 2nd consecutive year.
2020
- Economic Dividend for Gender Equality (EDGE) recognition for being the first company to earn Move level certification, globally.
To learn more about IFF’s Do More Good Plan, please visit iff.com/responsibilities/strategy-reporting and refer to IFF’s forthcoming 2021 sustainability report.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
_____________________________________
1 Pending finalization and approval by the Science Based Targets Initiative
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005605/en/
Contact information
Michael DeVeau
Chief Investor Relations & Communications Officer
212.708.7164
Michael.DeVeau@iff.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 10:00:00 EEST | Press release
Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and support, the Westcoast partnership helps cut the ‘meeting tax’, reducing set‑up friction and getting meetings started on time. The announc
Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 10:00:00 EEST | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the freedom to book their own trips without getting bogged down in manual approvals. Navan gives t
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 10:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic
Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 09:00:00 EEST | Press release
Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled the world’s first S250-FIT installation, developed in collaboration with Leo Cancer Care. The system was fully installed within a stan
CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results11.5.2026 08:10:00 EEST | Press release
Business Updates section, the first bullet of release dated April 23, 2026, at 10:04 p.m. PT/April 24, 2026, at 1:04 a.m. ET should read: In October 2025, Samsung Bioepis entered into a private label partnership with Cordavis for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia1. The updated release reads: SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
